About Ensol
History
History of Ensol, a leader of innovative new drug discovery
2024
Signing of L/O contract for expansion of P2K indications (Spine Biopharma/total contract amount: KRW 215.4 billion)
Phase 2 clinical trial completed (E1K, Knee Osteoarthritis)
2023
Withdrawal of application for preliminary examination for listing on KOSDAQ market
Phase 1 clinical trial completed (C1K, Monotherapy in healthy subjects)
Phase 1b clinical trial completed (E1K, Knee Osteoarthritis)
Investment attraction (KRW 5 billion, Humedics Co., Ltd.)
2022
Passed technology evaluation for listing on KOSDAQ market
MFDS IND approval for phase 1 clinical trial (C1K, Monotherapy in healthy subjects)
FDA IND approval for phase 3 clinical trial (P2K, Degenerative Disc Disease)
MFDS IND approval for phase 2 clinical trial (E1K, Knee Osteoarthritis)
2021
Submission of the phase 1a clinical study report (CSR) to the MFDS (E1K, Knee Osteoarthritis)
2020
MFDS IND approval for phase 1b clinical trial (E1K, Knee Osteoarthritis)
Designated as a Pre-Unicorn Company
Animal Osteoarthritis Drug EAD100 Global L/O(Global Top 10 Animal Health Company)
Animal Osteoarthritis Drug EAD100(JointVex) approved by Korea Animal and Plant Quarantine Agency(KAPQA)
2019
Application for license to sell animal osteoarthritis drug (EAD100) (Korea QIA)
2018
Phase 1 clinical trial approval for osteoarthritis drug (Engedi1000)
Ranked 347th in rapidly growing Asia-Pacific company in ‘Life science’ (biopharmaceutical included) selected by ‘Deloitte’ Global
Listed on KONEX (10th)
Expanded to CMC CDO for anticancer drug candidate material
Degenerative Disc Disease Drug Peniel2000(P2K) Global L/O(Spine Biopharma, LLC)
IND clinical trial application for osteoarthritis drug (Engedi1000)
Approval completed for clinical trial plan of animal drug ‘canine osteoarthritis drug (EAD100)’
2017
Development of pharmacokinetic mechanism prediction system (ETONS) ver 1.0
Discovery of type 1 diabetes drug (Shiloah1000)
2016
Launched high-purity phytochemical production/sales, analysis/separation service, peptide and chemical synthesis service
Discovered Alzheimer’s disease drug (Moria1000) candidate material
2015
Changed company name to Ensol Biosciences Inc.
Discovery of anticancer drug candidate (Charis1000)
2014
Approval of clinical trial for the degenerative disc disease drug (Peniel2000), Phase2b.
Completion of clinical trial for the degenerative disc disease drug (Peniel2000), Phase 1/2a
2013
Peniel2000 was published in the Spine online
2012
Approval of clinical trial for the degenerative disc disease drug (Peniel2000)
Technology Development Project Phase 2 Bio-hydrogen substantiation production agreements (Ministry of Land, Transport and Maritime Affairs)
2011
Development of new drug for rheumatoid arthritis treatment
Company building construction and moving (51, Techno 10-ro, Yuseong-gu, 34036, Daejeon, Korea)
License-out agreement for the joint development of osteoarthritis drug (Peniel 1000) and investment with Yuhan Corp.
2010
Development of protein interaction network analysis solution, NAS
Development of osteoarthritis drug (Peniel1000)
2009
License-out agreement for the joint development of degenerative disc disease (DDD), with Yuhan Corp.
Development of degenerative disc disease (DDD) drug called Peniel2000
Winning national project for the development of bio-hydrogen production technology from MLTM
2008
Development of integrated microbial genome analysis solution, EMFAS
Winning national project for the development of marine biodiversity information system project from NFRDA
Development of protein functional linkage analysis solution, FLiPS
2007
Winning technology innovation R&D project from SMB
2006
Winner of ‘RED HERRING ASIA 100’ in 2006
Development of protein identification solution, ProteinFinder
2005
Development of high-speed parallel processing BLAST, Hyper-BLAST
Collaboration agreement with CJ Corp.
2004
Protein informatics solution ProteinStar/TargetStar announced
Military service’s exemption company approved
2002
Selected as INNO-BIZ – Small and Medium Business Administration
Joint research agreement with CJ Bio R&D center
2001
Winner of IMT-2000 bioinformatics project from MAF (R&D Fund: 3.2 M$)
Award for excellent new technology (IT-Mark)
‘Certificate of Venture Business’ acquired from SMBA
‘Certificate of Company Research Institute’ approved from KOITA
Ensoltek Co., Ltd. founded by Hae-Jin Kim (Ph.D., CEO)
Headquarter : 51, Techno 10-ro, Yuseong-gu, Daejeon, 34036, Korea | TEL : +82-42-939-4500 | FAX : +82-42-939-4501
Copyright (c) 2019 Ensol Biosciences Inc. All Rights Reserved.